Abstract
l-Arginine is not only used as a precursor for protein synthesis, but it also functions as building stone for the synthesis of nitric oxide (NO), urea, ornithine, citrulline, creatinine, agmatine, glutamate, proline, and polyamines (Wu and Morris. Biochem J 336(Pt 1):1–17, 1998). Arginine is relatively abundant in the blood in its “free” form, and its blood concentration is mainly affected by food intake, by protein turnover, as well as by arginine supply via the kidney (Wu and Morris. Biochem J 336(Pt 1):1–17, 1998). This dibasic amino acid is conditionally essential during growth and is included in many pharmacological and nutritional formulations (Saitoh et al. J Toxicol Sci 39:41–50, 2014). In the urea cycle, arginine is derived from arginosuccinate and is further metabolized to produce urea and the amino acid ornithine (Wu and Morris. Biochem J 336(Pt 1):1–17, 1998). De novo biosynthesis of arginine uses citrulline as a precursor which, in turn, can be supplied from intestinal glutamine metabolism (Saitoh et al. J Toxicol Sci 39:41–50, 2014). Besides dietary intake, several factors affect the bioavailability of dietary arginine, such as the levels of lysine, manganese, n-3 fatty acids in the diet, and circulating hormones including cortisol, growth hormone, leptin, cytokines, endotoxins, as well as other biomolecules, such as creatine, lactate, ornithine, and methylarginine (Wu et al. Amino Acids 37:153–168, 2009). Here, citrulline is converted to arginine in the body, and pharmacokinetic studies indicate that citrulline is better absorbed and, hence, has a greater systemic bioavailability than arginine (Cynober. J Nutr, 6th Amino acid assessment workshop 1646S–1649S, 2007). Dietary citrulline is also capable of increasing blood levels of arginine and NO without affecting urea output (Virarkar et al. Crit Rev Food Sci Nutr 53(11):1157–1167, 2013).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Wu G, Morris Jr SM. l-Arginine metabolism: nitric oxide and beyond. Biochem J. 1998;336(Pt 1):1–17.
Saitoh W, Yamauchi S, Watanabe K, Takasaki W, Mori K. Metabolomic analysis of l-arginine metabolism in acute hepatic injury in rats. J Toxicol Sci. 2014;39:41–50.
Wu G, Bazer FW, Davis TA, Kim SW, Li P, Marc Rhoads J, Carey Satterfield M, Smith SB, Spencer TE, Yin Y. l-Arginine metabolism and nutrition in growth, health and disease. Amino Acids. 2009;37:153–68.
Cynober L. Pharmacokinetics of l-arginine and related amino acids. J Nutr, 6th Amino acid assessment workshop. 2007. p. 1646S–9S.
Virarkar M, Alappat L, Bradford PG, Awad AB. l-Arginine and nitric oxide in CNS function and neurodegenerative diseases. Crit Rev Food Sci Nutr. 2013;53(11):1157–67.
Castillo L, Chapman TE, Yu YM, Ajami A, Burke JF, Young VR. Dietary l-arginine uptake by the splanchnic region in adult humans. Am J Physiol Endocrinol Metab. 1993;265:E532–9.
Krause MS, McClenaghan NH, Flatt PR, de Bittencourt PI, Murphy C, Newsholme P. l-arginine is essential for pancreatic β-cell functional integrity, metabolism and defense from inflammatory challenge. J Endocrinol. 2011;211(1):87–97.
Fotiadis D, Yoshikatsu K, Palacín M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 2013;34(2-3):139–58.
Da Silva MFL, Floeter-Winter LM. Arginase in Leishmania. In: Santos ALS, Branquinha MH, D’Avila-Levy CM, Kneipp LF, Sodré CL, editors. Proteins and proteomics of Leishmania and Trypanosoma: subcellular biochemistry, vol. 74. Dordrecht: Springer; 2014. p. 103–17.
Kavanaugh MP. Voltage dependence of facilitated l-arginine flux mediated by the system y+ basic amino acid transporter. Biochemistry. 1993;32(22):5781–5.
Closs EI, Boissel JP, Habermeier A, Rotmann A. Structure and function of cationic amino acid transporters (CATs). J Membr Biol. 2006;213(2):67–77.
Rothenberg ME, Doepker MP, Lewkowich IP, Chiaramonte MG, Stringer KF, Finkelman FD, MacLeod CL, Ellies LG, Zimmermann N. Cationic amino acid transporter 2 regulates inflammatory homeostasis in the lung. Proc Natl Acad Sci U S A. 2006;103(40):14895–900.
Yeramian A, Martin L, Serrat N, Arpa L, Soler C, Bertran J, McLeod C, Palacin M, Modolell M, Lloberas J, Celada A. Arginine transport via cationic amino acid transporter 2 plays a critical regulatory role in classical or alternative activation of macrophages. J Immunol. 2006;176(10):5918–24.
Hrabak A, Bajor T, Temesi A, et al. The inhibitory effect of nitrite, a stable product of nitric oxide (NO) formation, on arginase. FEBS Lett. 1996;390(2):203–6.
Felig P, Wahren J, Räf L. Evidence of inter-organ amino-acid transport by blood cells in humans. Proc Natl Acad Sci U S A. 1973;70(6):1775–9.
Winter CG, Christensen HN. Migration of amino acids across the membrane of the human erythrocyte. J Biol Chem. 1964;239:872–8.
Drewes LR, Conway WP, Gilboe DD. Net amino acid transport between plasma and erythrocytes and perfused dog brain. Am J Physiol Endocrinol Metab. 1977;233:E320.
Young JD, Jones SEM, Ellory JC. Amino acid transport in human and in sheep erythrocytes. Proc R Soc Lond B. 1980;209:355–75.
Harvey C, Ellory JC. Identification of amino acid transporters in the red blood cell. In: Fleischer S, Fleischer B, editors. Methods in enzymology. New York: Academic; 1989. p. 122–60.
Vadgama JV, Castro M, Christensen HN. Characterization of amino acid transport during erythroid cell differentiation. J Biol Chem. 1987;262(27):13273–84.
Ramírez-Zamora S, Méndez-Rodríguez ML, Olguín-Martínez M, Sánchez-Sevilla L, Quintana-Quintana M, García-García N, Hernández-Muñoz R. Increased erythrocytes by-products of l-arginine catabolism are associated with hyperglycemia and could be Involved in the pathogenesis of type 2 diabetes mellitus. PLoS One. 2013;8(6):e66823.
Moore WT, Rodarte J, Smith Jr LH. Urea synthesis by hemic cells. Clin Chem. 1964;10(2):1059–65.
Hagenfeldt L, Arvidsson A. The distribution of amino acids between plasma and erythrocytes. Clin Chim Acta. 1980;100:133–41.
Cortese-Krott MM, Kelm M. Endothelial nitric oxide synthase in red blood cells: key to a new erythrocrine function? Redox Biol. 2014;2:251–8.
Chen LY, Mehta JL. Variable effects of l-arginine analogs on l-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J Pharmacol Exp Ther. 1996;276:253–7.
Mehta JL, Mehta P, Li D. Nitric oxide synthase in adult red blood cells: vestige of an earlier age or a biologically active enzyme? J Lab Clin Med. 2000;135(6):430–1.
Muller G, Goettsch C, Morawietz H. Oxidative stress and endothelial dysfunction. Hamostaseologie. 2007;27(1):5–12.
Chen LY, Mehta JL. Evidence for the presence of l-arginine-nitric oxide pathway in human red blood cells: relevance in the effects of red blood cells on platelet function. J Cardiovasc Pharmacol. 1998;32(1):57–61.
Kang ES, Ford K, Grokulsky G, Wang YB, Chiang TM, Acchiardo SR. Normal circulating adult human red blood cells contain inactive NOS proteins. J Lab Clin Med. 2000;135(6):444–51.
Kleinbongard P, Keymel S, Kelm M. New functional aspects of the l-arginine-nitric oxide metabolism within the circulating blood. Thromb Haemost. 2007;98(5):970–4.
Gladwin MT, Crawford JH, Patel RP. The biochemistry of nitric oxide, nitrite, and hemoglobin: role in blood flow regulation. Serial review: biomedical implications for hemoglobin interactions with nitric oxide. Free Radic Biol Med. 2004;36(6):707–17.
Cylwik D, Mogielnicki A, Buczko W. l-arginine and cardiovascular system. Pharmacol Rep. 2005;57:14–22.
Kosaka H, Hisatome I, Ogino K, Tanaka Y, Osaki S, Kitamura H, et al. Excess purine degradation in muscle of chronic hemodialysis patients. Nephron. 1993;64:481–2.
Tanaka Y, Hisatome I, Kinugaqa T, Tanaka H, Tomikura Y, Ando F, et al. Excessive purine degradation during semi-ischemic forearm test in patients with diabetes mellitus. Intern Med. 2003;42:788–92.
Rexroth W, Hageloch W, Isgro F, Koeth T, Manzl G, Weicker H. Influence of peripheral arterial occlusive disease on muscular metabolism. Part 1: changes in lactate, ammonia and hypoxanthine concentration in femoral blood. Klin Wochenschr. 1989;67:576–82.
Srinivasan S, Hatley ME, Bolick DT, Palmer LA, Edelstein D, Brownlee M, Hendrick CC. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia. 2004;47:1727–34.
Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D. Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care. 2000;23:234240.
Salceda R, Vilchis C, Coffe V, Hernández-Muñoz R. Changes in the redox state in the retina and brain during the onset of diabetes in rats. Neurochem Res. 1998;23:893–7.
Memisoğullari R, Taysi S, Bakan E, Capoglu I. Antioxidant status and lipid peroxidation in type II diabetes mellitus. Cell Biochem Funct. 2003;21:291–6.
Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med. 1998;338:265–6.
Fulop M, Murthy V, Michilli A, Nalamati J, Qian Q, Saitowitz A. Serum β-hydroxybutyrate measurement in patients with uncontrolled diabetes mellitus. Arch Intern Med. 1999;159:381–4.
Obrosova IG, Drel VR, Kumagai AK, Szábo C, Pacher P, Stevens MJ. Early diabetes-induced biochemical changes in the retina: comparison of rat and mouse models. Diabetologia. 2006;49:2525–33.
Cheung AK, Fung MK, Lo AC, Lam TT, So KF, Chung SS, Chung SK. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes. 2005;54:3119–25.
Cruz JW, Oliveira MA, Hohman TC, Fortes ZB. Influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetes. Eur J Pharmacol. 2000;391:163–74.
Miwa K, Nakamura J, Hamada Y, Naruse K, Nakashima E, Kato K, et al. The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract. 2003;60:1–9.
Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes. 2004;53:2404–11.
Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991;40:405–11.
Wu G, Meininger CJ. l-Arginine nutrition and cardiovascular function. J Nutr. 2000;130:2626–9.
Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, et al. Metabolite profiles and the risk of develo** diabetes. Nat Med. 2011;17:448–53.
Pernow J, Jung C. Arginase as a potential target in the treatment of cardiovascular disease: reversal of l-arginine steal? Cardiovasc Res. 2013;98(3):334–43.
Casanello P, Escudero C, Sobrevia L. Equilibrative nucleoside (ENTs) and cationic amino acid (CATs) transporters: implications in foetal endothelial dysfunction in human pregnancy diseases. Curr Vasc Pharmacol. 2007;5(1):69–84.
Phillips MM, Sheaff MT, Szlosarek PW. Targeting l-arginine-dependent cancers with l-arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat. 2013;45(4):251–62.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Contreras-Zentella, M.L., Hernández-Muñoz, R. (2017). Erythrocytes By-Products of l-Arginine Catabolism. In: Patel, V., Preedy, V., Rajendram, R. (eds) L-Arginine in Clinical Nutrition. Nutrition and Health. Humana Press, Cham. https://doi.org/10.1007/978-3-319-26009-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-26009-9_8
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-26007-5
Online ISBN: 978-3-319-26009-9
eBook Packages: MedicineMedicine (R0)